Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

digital therapy

- PMLiVE

NICE backs Pfizer drug in kidney cancer

Inlyta near end of two-year struggle for recommendation

- PMLiVE

Cancer Drugs Fund is not NICE replacement

Malcolm Qualie, pharmacy lead for specialised services within NHS England, speaks to PMLiVE

- PMLiVE

UK Labour party pledges £330m cancer fund

Says will improve access to cancer drugs, radiotherapy and surgery if elected

UK flag

Education at heart of new UK diabetes guidelines

NICE recommends new standards for adults with type 1 and children with either type 1 or type 2

National Institute for Health and Care Excellence NICE logo

Janssen sways NICE with Stelara discount

UK health watchdog set to recommend drug in psoriatic arthritis after agreeing patient access scheme

- PMLiVE

OPEN Health launches market access division

OPEN Access Consulting will be headed by Cathy Wright and Cathy Jarrold

Can Cinderella save us?

NICE wants responsible use of antibiotics in pneumonia

Drugs often prescribed to wrong patients

- PMLiVE

NICE backtracks on Gazyvaro rejection

Roche agrees to patient access scheme to help gain leukaemia recommendation

- PMLiVE

NICE overturns negative Glivec guidance

Recommends drug for reimbursement in GIST four years after rejection

- PMLiVE

NICE set to back Alexion’s costly ‘ultra-orphan’ drug

Final draft guidance recommends aHUS treatment Soliris

- PMLiVE

NICE backs drug to cut alcohol consumption

Final guidance for Lundbeck’s Selincro for use on NHS in England

- PMLiVE

NICE wants more info on Novartis’ Xolair in chronic hives

Says company must provide more data on the drug's effectiveness

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links